Considering the rapid improvement in the treatment of lung cancer, particularly non-small-cell lung cancer (NSCLC), physicians now have several options of personalized treatments targeting driver genes, such as EGFR mutations, ALK rearrangements, ROS1 rearrangements, and BRAF mutations or combination therapies comprising immunotherapy and anticancer drugs [2–6]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.